Igor I. Rybkin

3.6k citations

41 papers · 1.8k indexed · 2 hit papers · h-index 17

Impact in

Behavioral Neuroscience top 5%
- Stress Responses and Cortisol
Endocrine and Autonomic Systems top 5%

Papers in

Oncology 25
- Colorectal Cancer Treatments and Studies 8
- Cancer Immunotherapy and Biomarkers 8
- Pancreatic and Hepatic Oncology Research 4
- Peptidase Inhibition and Analysis 4
Pulmonary and Respiratory Medicine 20
- Lung Cancer Treatments and Mutations 16
- Lung Cancer Diagnosis and Treatment 7

Co-authors: Donna H. Ryan Gennady Smagin Ruth B.S. Harris Rhonda Bassel‐Duby John M. Shelton Melissa L. Johnson Minal Barve James G. Christensen
Journals: Journal of Clinical Oncology (11 papers)Journal of Thoracic Oncology (8 papers)Annals of Oncology (5 papers)International Journal of Radiation Oncology*Biology*Physics (4 papers)Journal of Biological Chemistry (2 papers)
Partner nations: United States Netherlands Italy

In The Last Decade

Igor I. Rybkin

40 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1) 2022 · 206 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Journal of Clinical Oncology
2005 Cell Metabolism

Peers

Countries citing papers authored by Igor I. Rybkin

Since Specialization

Citations

This map shows the geographic impact of Igor I. Rybkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor I. Rybkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor I. Rybkin more than expected).

Fields of papers citing papers by Igor I. Rybkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor I. Rybkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor I. Rybkin. The network helps show where Igor I. Rybkin may publish in the future.

Co-authors

The 25 scholars most cited alongside Igor I. Rybkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Igor I. Rybkin Line = papers co-authored together Igor I. Rybkin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary International Journal of Radiation OncologyBiologyPhysics ·Charles B. Simone, Arya Amini, Indrin J. Chetty, J. Isabelle Choi, Stephen G. Chun, Jessica Donington, Martin J. Edelman, Kristin Higgins, Larry L. Kestin, Pranshu Mohindra, Benjamin Movsas, George Rodrigues, Kenneth E. Rosenzweig, Igor I. Rybkin, Annemarie F. Shepherd, Ben J. Slotman, Andrea Wolf, Joe Y. Chang	2025	3
2	MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC Journal of Thoracic Oncology ·Jeffrey Clarke, Enriqueta Felip, B.T. Li, J.C. Ruffinelli, Pilar Garrido, Jon Zugazagoitia, Sarah B. Goldberg, Suresh S. Ramalingam, Iván Victoria, Sonam Puri, David R. Gandara, HE Hong-pu, Sally Edmonds, Kerry Palmer, Wendy Snyder, Ramaswamy Govindan, Igor I. Rybkin	2023	12
3	43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy Annals of Oncology ·Ticiana Leal, David Berz, Igor I. Rybkin, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, A. Meunier, David S. Hong, Ronald Shazer, Xiaohong Yan, Aurora de la Vega de Deza, Kai He	2022	13
4	O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup Annals of Oncology ·Jaffer A. Ajani, Farid El Hajbi, David Cunningham, María Alsina, Peter Thuss‐Patience, Giorgio V. Scagliotti, Marc Van den Eynde, Igor I. Rybkin, Lin Shen, Ken Kato, S Kim, H. I. Ogan, Wentao Yu, Pilar Escos, Eric Van Cutsem	2021	5
5	1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy Annals of Oncology ·Ticiana Leal, David Berz, Igor I. Rybkin, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, Edward B. Garon, David S. Hong, Ronald Shazer, Xin Yan, Aurora de la Vega de Deza, Kai He	2021	15
6	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC JTO Clinical and Research Reports ·D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Eric Angevin, David S. Hong, Igor I. Rybkin, Minal Barve, Todd M. Bauer, Angelo Delmonte, Martin Dunbar, Monica Motwani, Apurvasena Parikh, Fahrul Riski, Jun Wu, Vincent Blot, Karen Kelly	2021	22
7	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer International Journal of Radiation OncologyBiologyPhysics ·Arya Amini, Vivek Verma, Charles B. Simone, Indrin J. Chetty, Stephen G. Chun, Jessica Donington, Martin J. Edelman, Kristin Higgins, Larry L. Kestin, Benjamin Movsas, George Rodrigues, Kenneth E. Rosenzweig, Igor I. Rybkin, Ben J. Slotman, Andrea Wolf, Joe Y. Chang	2021	30
8	Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response Cureus ·Smith KG, Mohamed Elgamal, Igor I. Rybkin	2021	2
9	Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update. Journal of Clinical Oncology ·Lauren A. Byers, Kathryn A. Gold, Julio A. Peguero, Melissa L. Johnson, Jorge J. Nieva, Wael A. Harb, Alberto Chiappori, Igor I. Rybkin, James Strauss, David E. Gerber	2021	17
10	99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation Journal of Thoracic Oncology ·Meghan Evans, Y GUOAmy, Igor I. Rybkin, Alexander I. Spira, K. Papadopoulos, Joshua K. Sabari, Melissa L. Johnson, Rebecca S. Heist, Lyudmila Bazhenova, Minal Barve, J. Troyano, Karen Velastegui, Cornelius Cilliers, Peter Olson, James G. Christensen, Thian Kheoh, Richard C. Chao, Jennyfer Larissa Tábora Reyes	2021	58
11	Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2) Journal of Thoracic Oncology ·David R. Spigel, Robert M. Jotte, John Nemunaitis, Halcyon Hayward, Jeffrey Schneider, Jerome H. Goldschmidt, Світлана ЖАРАЯ, David Berz, Lasika Seneviratne, Gourab Kalita, Han Lin-jin, Kartik Konduri, Meng Xia, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, David Ferry, Leena Gandhi, Bo H. Chao, Igor I. Rybkin	2020	36
12	American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020 Journal of Thoracic Oncology ·Stephen G. Chun, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Kristin Higgins, Larry L. Kestin, Benjamin Movsas, George Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor I. Rybkin, Andrea Wolf, Joe Y. Chang	2020	15
13	American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC Journal of Thoracic Oncology ·Kristin Higgins, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Stephen G. Chun, Larry L. Kestin, Benjamin Movsas, George Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor I. Rybkin, Andrea Wolf, Joe Y. Chang	2020	16
14	P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy Journal of Thoracic Oncology ·John Nemunaitis, Hossein Borghaei, Wallace Akerley, Shirish M. Gadgeel, Alexander I. Spira, Igor I. Rybkin, Heidi B. Nafda, Isan Chen, James G. Christensen, Diane Potvin, Karen Velastegui, Matteo Levisetti, Hatim Husain	2017	3
15	PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC Journal of Thoracic Oncology ·Igor I. Rybkin, Egbert F. Smit, Hans‐Georg Kopp, Dong‐Wan Kim, Alexander I. Spira, Alfredo Berruti, Dae Ho Lee, Noemı́ Reguart, Mikhail Akimov, Karl Schumacher, Allison Upalawanna, Matthew Squires, Daniel Shao-Weng Tan	2016	1
16	Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET) Annals of Oncology ·Lyudmila Bazhenova, Ranee Mehra, Tünde Nagy, Luigi Cavanna, J.-S. Lee, J. Y. Han, Nayara Mendes Foresto, Balázs Halmos, Halcyon Hayward, Marshall T. Schreeder, Igor I. Rybkin, Firas Badin, Raul Mena, Pasi A. Jänne, James G. Christensen, Vanessa Tassell, Richard C. Chao, Heidi B. Nafda, D.-W. Kim	2016	2
17	Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET). Journal of Clinical Oncology ·Igor I. Rybkin, Ebenezer A. Kio, Ashiq Masood, Halcyon Hayward, Balázs Halmos, Collin M. Blakely, Keith D. Eaton, Neelesh Sharma, John Nemunaitis, Larry Lain, Yanis Boumber, Raul Mena, Hamid Mirshahidi, Pasi A. Jänne, James G. Christensen, Richard C. Chao, Vanessa Tassell, Heidi B. Nafda, Marshall T. Schreeder	2016	6
18	Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle Cell Metabolism ·Zoltàn Arany, Huamei He, Jiandie D. Lin, Kirsten Hoyer, Christoph Handschin, Okan Toka, Ferhaan Ahmad, Takashi Matsui, Sherry Chin, Pei-Hsuan Wu, Igor I. Rybkin, John M. Shelton, Monia Manieri, Saverio Cinti, Frederick J. Schöen, Rhonda Bassel‐Duby, Anthony Rosenzweig, Joanne S. Ingwall, Bruce M. Spiegelman Hit paper breakdown →	2005	565
19	Conditional Expression of SV40 T-antigen in Mouse Cardiomyocytes Facilitates an Inducible Switch from Proliferation to Differentiation Journal of Biological Chemistry ·Igor I. Rybkin, David W. Markham, Zhen Yan, Rhonda Bassel‐Duby, R. Sanders Williams, Eric N. Olson	2003	40
20	α1A Adrenergic Receptor Induces Eukaryotic Initiation Factor 4E-binding Protein 1 Phosphorylation via a Ca2+-dependent Pathway Independent of Phosphatidylinositol 3-kinase/Akt Journal of Biological Chemistry ·Igor I. Rybkin, Peggy Ouédraogo Segda, Shofie Lathifah, Richard Z. Lin, Lisa M. Ballou	2000	21

About Igor I. Rybkin

Igor I. Rybkin is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Behavioral Neuroscience, Family Practice and Cancer Research, having authored 41 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Diagnosis and Treatment (7 papers), Pancreatic and Hepatic Oncology Research (4 papers), Phagocytosis and Immune Regulation (4 papers), Peptidase Inhibition and Analysis (4 papers) and Cancer Genomics and Diagnostics (4 papers). The work is most often cited by research in Behavioral Neuroscience (169 citations), Endocrine and Autonomic Systems (135 citations), Physiology (488 citations), Oncology (492 citations) and Biological Psychiatry (33 citations). Igor I. Rybkin has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Donna H. Ryan, Gennady Smagin, Ruth B.S. Harris, Rhonda Bassel‐Duby, John M. Shelton, Melissa L. Johnson, Minal Barve, James G. Christensen, Karen Velastegui and Huamei He. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact